Transcriptional regulation of E-cadherin and oncoprotein E7 by valproic acid in HPV positive cell lines

Ebrahim Faghihloo 1, Abolfaz Akbari 2, Fatemeh Adaminezhad-Fard 3, Talat Mokhtari-Azad 3*

1 Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran
3 Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article type: Original article

Article history:
Received: Feb 22, 2015
Accepted: Dec 24, 2015

Keywords:
Cervical cancer
E-cadherin
HPV
Valproic acid

ABSTRACT

Objective(s): Valproic acid (VPA) has proven to be as one of the most promising useful drug with anticancer properties. In this study, we investigate the VPA effects on E-cadherin expression in HeLa, TC1, MKN45, and HCT116 cell lines. This study assesses the effects of VPA on human papillomavirus E7 expression in HPV positive cell lines.

Materials and Methods: Cells were treated by 2 mmol/L VPA and expression of E-cadherin and E7 was analyzed by quantitative real-time PCR. Student's t test and ANOVA were used to determine changes in expression levels.

Results: The results revealed that mean of E-cadherin expression is increased by VPA 1.9 times in HCT116 and MKN45 cell lines, also the mean of E-cadherin mRNA levels is up-regulated 2.9 times in HeLa and TC1 cell lines. So, E-cadherin augmentation induced by VPA in HeLa and TC1-1, HPV positive cell lines, is higher than HPV negative cell lines MKN45 and HCT116. The mean of HPV E7 expression is decreased by VPA, 4.6 times in in HeLa and TC1-1 cell lines.

Conclusion: This study demonstrates that re-expression of E-cadherin by VPA in HPV positive cell lines is more than HPV negative cell lines. Whereas, HPV E7 reduces the expression of E-cadherin, reduction of HPV E7 expression by VPA is related to more augmentation of E-cadherin in HPV positive cell lines. So, this study demonstrates that VPA has more anticancer properties in HPV positive cell lines, and could potentially be a promising candidate for cervical cancer treatment.

Introduction

Cervical cancer is one of the most common cancers in women worldwide with more than 200,000 deaths, annually (1). Approximately 80% of them live in developing countries where this disease is detected at late stage; so, new treatment drugs for cervical cancer are needed (2, 3).

Development of cervical cancer is caused by high-risk human papillomaviruses (hrHPVs) (4). They are small, nonenveloped, and nonlytic viruses with dsDNA genome that are tropic for squamous epidermis. The cervical carcinogenesis is associated with E6 and E7 oncoproteins from hrHPVs (4). E6 and E7 viral oncogenic proteins inactivate two cellular tumor suppressor proteins p53 and pRB, respectively (5, 6), and are necessary for cells proliferation and DNA damage that eventually lead to cancer (7).

The development of cervical cancer related to changes in epigenetic patterns of cells such as DNA methylation, histone methylation, and histone acetylation (8). Histone acetylation is one of the most important epigenetic mechanisms that neutralizes the positive charge of histone proteins, unfolds the chromatin structure and associated DNA, and induces transcription and gene expression (9).

The acetylation of histone proteins is regulated by histone acetyltransferase (HATs) and histone deacetylases (HDACs). HDACs remove the acetyl groups on the lysine residues of histones and induce positive charge on histone proteins, this leads to aberrant transcription and gene suppression. So, HDACs could reduce the expression of tumor suppressor genes to development of cancer (10).

Histone deacetylase inhibitors (HDACIs) have appeared as the promising drugs for cancer (11, 12). HDACIs have been classified to 5 groups: 1. short chain fatty acids (e.g., butyrates and valproic acid), 2. organic hydroxamic acids (e.g., suberoylanilide bishydroxamine (SAHA) and trichostatin A (TSA)), 3. sulfonamide anilides, 4. benzamides (e.g., MS-275), 5. cyclic tetrapeptides (13).

*Corresponding author: Talat Mokhtari-Azad. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. email: mokhtari@sina.tums.ac.ir
Among HDACIs, valproic acid (VPA) has been demonstrated as a drug with anticancer properties. VPA is used for treatment of cluster migraine, headaches, and epilepsy (14), but antineoplastic activity of VPA was shown in 1997 (15). VPA increases apoptosis and reduces angiogenic activity in various tumor cells (16). It also inhibits invasion and migration of tumor cells by several mechanisms (16-19).

To start the process of invasion and metastasis, a malignant cell must first break away from the cancerous tumor. In cancer cells, the expression of adhesion molecules seems to be reduced. E-cadherin is one of the most important adhesion molecules encoded by CDH1 gene, and the dominant epithelial cell-adhesion molecule. This protein is expressed on basal and suprabasal cells and plays important role in epithelial structural integrity (20, 21). The suppression of E-cadherin expression has been widely reported in different epithelial tumors (22-27). The loss of E-cadherin is associated with invasion and metastasis (28).

In this work, we compare the effects of VPA on E-cadherin expression in two groups of cell lines, HPV positive and HPV negative cell lines. Also, we study the effects of VPA on E7 oncoprotein expression in HPV positive cell lines.

Materials and Methods

Cell culture

The HPV positive cell line; HeLa, a cervical carcinoma cell line that contains HPV18 DNA, and TC1, which is transduced to express the E6 and E7 oncoproteins of HPV16, were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco). Growth media was supplemented with 10% heat inactivated fetal calf serum (Life Technologies, Camarillo, CA, USA), 100 μg/ml penicillin/streptomycin (Invitrogen, Life Technologies, Camarillo, CA, USA), 100 μg/ml amphotericin B and 2 mM L-glutamine (Sigma-Aldrich, MO, USA). The HPV negative cell lines; HCT116 and MKN45, were also cultured in the same condition. All of the cell lines were maintained in humidified incubator with 5% CO2.

Valproic acid preparation

Valproate sodium salt was prepared from sigma (Sigma-Aldrich, MO, USA) and was dissolved in phosphate buffered saline (PBS) to 1, 2, and 5 mM concentrations.

Proliferation assay

Cell proliferation was performed using the 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) dye reduction assay. HeLa, TC1, HCT116, and MKN45 cell lines were seeded at a density of 5x10^4 per well in 96 well culture plates and incubated overnight with DMEM containing 10% fetal calf serum. After 24 hr, the cells were treated with medium containing VPA at concentrations of 0, 1, 2, and 5 mmol/L, for three days. After 24, 48, and 72 hr, MTT was added at concentration of 0/5 mg/ml for 4 hr. The absorbance was determined at 570 nm.

RNA preparation

The four cell lines (HCT116, MKN45, HeLa, and TC1) were cultured in 12 well culture plates to 80 percent confluency and were treated with medium containing 2 mmol/L VPA for 48 hr. According to experimental studies, our experiments were performed three times to achieve valid results; so, we did real-time PCR analysis for each experiment using 3 samples. The cells were harvested and resuspended in 250 μl volume of sterile PBS. Total RNA was extracted from cells using TriPure total RNA isolation Kit according to the manufacturer's procedure (Roche Applied science, Indianapolis, IN, USA). Extracted RNA concentration and purity were analyzed at the wavelength of 260 nm by nanodrop spectrophotometry (Eppendorf, Hamburg, Germany). RNA integrity was visually assessed with 1% agarose gel electrophoresis. The RNA with absorption ratio OD 260 nm OD 280 nm between 1/8 and 2 was used for cDNA synthesis.

cDNA synthesis

cDNA was prepared from total RNA by reverse transcription using M-MuLV reverse transcriptase (Fermentas, Vilnius, Lithuania), random hexamers, and RNase inhibitor (Vivantis). One μg of RNA was added by 2 μl of 10 mM dNTPs along with 1 μl of (0.2 μg/μl) random hexamer, 1 μl (20 u/μl) of M-MuLV, and 0.5 μl of RNase inhibitor in a sterile microcentrifuge tube. The final volume was made up to 20 μl by adding sterile distilled water and was mixed well. These tubes were incubated at room temperature for 10 min and then were incubated at 42 °C for one hr. The M-MuLV enzyme inactivation step was done by a step for 10 min at 70 °C. The synthesized cDNA was diluted 10 times in sterile distilled water and was used as a template for quantitative real-time PCR analysis.

Quantitative real-time PCR

Expression of E-cadherin mRNA was analyzed by quantitative real-time PCR using the SYBR Premix Ex Taq II kit (TAKARA Bio Inc., Otsu, Japan) on an Applied Biosystems® StepOnePlus™ Real-Time PCR system (Applied Biosystems, Foster city, CA, USA). Quantitative real-time PCR was performed using the following primer sequences: E-cadherin, forward: 5’-AGGGGTAAGCACAACACAGCA-3’ and reverse: 5’-GTTATTGGGGGGCATACATCA-3’; HPV E7, forward: 5’-ATGACATGGG ATACACCTAC-3’ and reverse: 5’-TTATGTTTCTGAGAACAGATG-3’, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
forward: 5’-ATGTTGCTGATGGGTGTGAA-3’ and reverse: 5’- GGTGCTAAGCAGTGGTGGT-3’. Briefly, 10 μl SYBR Premix Ex Taq II (2×), 0.4 μl ROX Reference Dye (50x), and 0.8 μl of forward and reverse primers with 2 μl of 1/10 diluted cDNA were used in a total volume of 20 μl. The temperature profile for all genes was 95 °C for 1 min; 40 cycles of 95 °C for 15 sec, 55 °C for 30 sec, and 72 °C for 30 sec; melting curve program (60-95 °C). All samples were run in triplicate simultaneously with negative controls. The threshold cycle (ct) of E-cadherin mRNA level was analyzed. Each experiment was done three times (n=3).

**Statistical analysis**

The unpaired, two-tailed student’s t was done to analyze the statistical differences between groups using Graph-Pad Prism software. mRNA levels comparisons between groups were analyzed using ANOVA test. A P-value less than 0.05 (P<0.05) was considered to be statistically significant for the differences and determined by asterisk in the corresponding figures.

**Results**

Optimization of the valproic acid concentration for E-cadherin expression

The cell lines were treated by 1, 2, and 5 mM VPA and harvested 24, 48, and 72 hr after treatment. MMT assay and quantitative real-time PCR results for E-cadherin mRNA levels showed that 2 mM VPA after 48 hr gave the highest amount of E-cadherin expression (data not shown).

Valproic acid up-regulated E-cadherin expression in HPV negative cell lines

Two HPV positive cell lines, HCT116 and MKN45, were treated by 2 mM VPA to study the E-cadherin mRNA level changes. Cells were harvested 48 hr after treatment, total RNA was extracted, and cDNA was synthesized by 1 μg RNA. Then E-cadherin expression was analyzed by quantitative real-time PCR. Each experiment was done three times (n=3). The results revealed that E-cadherin expression is increased 1.7 and 2 times in HCT116 and MKN45 cell lines in comparison to control cells with P-value=0.0423 and P-value = 0.0042, respectively (Figure 1A, B).

E-cadherin expression is increased in HPV positive cell lines by valproic acid

The two HPV positive cell lines, HeLa and TC1, were treated by 2 mM VPA, and E-cadherin mRNA level was analyzed. Each experiment was done three times (n=3). The results showed that E-cadherin mRNA level is significantly up-regulated, 3.2 and 2.6 times in HeLa and TC1 cell lines with P-value = 0.0028 and P-value = 0.0089, respectively (Figure 2A, B).

The E-cadherin augmentation is induced by valproic acid in HPV positive cell lines higher than HPV negative cell lines are

The experiments showed that E-cadherin expression is increased by VPA in both HPV positive and negative cell lines; whereas, E-cadherin augmentation in HeLa and TC1 (Mean=2.9), HPV positive cell lines, is higher than HPV negative cell lines; whereas, E-cadherin augmentation in HeLa and TC1 (Mean=1.85) (Figure 3).

Valproic acid down-regulated HPV E7 expression in HeLa and TC1 cell lines

Previous studies revealed the relationship between HPV E7 oncoprotein and E-cadherin expression. One study showed that expression of the HPV16 E7 reduces the expression of E-cadherin in

![Figure 1. E-cadherin expression is increased in human papillomavirus negative cell lines by valproic acid.](image)
Figure 2. Valproic acid up-regulated E-cadherin expression in human papillomavirus positive cell lines. Hela and TC1 cell lines were cultured by DMEM containing 2 mM VPA. After 48 hr treatment, cells were harvested and fold change of E-cadherin expression was analyzed by real time PCR using the 2-ΔΔCt method. (A) E-cadherin mRNA level in Hela cell line treated by VPA. (B) E-cadherin mRNA level in TC1 cell line treated by VPA. Each experiment was done three times (n=3). * P < 0.05, ** P < 0.01

Figure 3. The E-cadherin augmentation induced by valproic acid in HPV positive cell lines is higher than HPV negative cell lines

Figure 4. Valproic acid down-regulated HPV E7 expression in human papillomavirus positive cell lines. Hela and TC1 cell lines were treated by 2 mM VPA. After 48 hr of treatment, cells were harvested and fold change of HPV E7 expression was analyzed by real time PCR using the 2–ΔΔCt method. (A) HPV E7 expression in Hela cell line treated by VPA. (B) HPV E7 expression level in TC1 cell line treated by VPA. Each experiment was done three times (n=3). Error bars represent SEM. * P < 0.05, ** P < 0.01

Discussion

Epigenetic is composed inducible genetic changes that regulates gene expression. DNA methylation and histone acetylation are two most common mechanisms that induce epigenetic changes (32). DNA methylation occurs at cytosine within CpG islands and it is catalyzed by DNA methyltransferases (DNMTs) protein family (33). DNA methylation directly interferes with transcription factors binding to recognition regions in promoter sites, and causes transcriptional suppression (34). Interaction of DNMTs with other chromatin...
modifying enzymes such as HDACs and histone methyltransferase brings these proteins in the vicinity of promoter sites and alters gene expression (35-38).

Positive charge at lysine residues neutralized by histone acetylation, loosen the chromatin structure that finally causes transcriptionally active chromatin (9, 10). DNMTs bring HDACs in the vicinity of promoter regions, cause local histone deacetylation, and condense chromatin structure that reduce gene expression levels by limiting accessibility of transcription factors to this sites (39). HDACs include 18 genes that are divided into 4 classes (13).

HDACIs have emerged as the hopeful clinical drugs for cancer (11, 12). VPA has proven as one of the most encouraging useful therapeutics with anticancer properties. In comparison with other HDACIs such as trapoxin and trichostatin A that have toxic side effects, VPA is relatively nontoxic and safe in vivo (13). VPA inhibits invasion and migration of tumor cells by several mechanisms (16-19).

During epithelial to mesenchymal transition (EMT) process, a malignant cell can break away from the cancerous tumor (40). A critical molecular feature of EMT is the downregulation of E-cadherin (41). E-cadherin acts as a tumor suppressor protein and inhibits invasion and metastasis. (42).

EMT provides molecular mechanisms for cervical cancer metastasis, and decreased or aberrant expression of E-cadherin have been reported in cervical carcinoma (43-45).

Carcinoma of the cervix is the second most common cancer in women worldwide (1). Development of this cancer is caused by the integration of hrHPVs in the host genome (4 HPV E6 and E7 viral proteins may induce EMT in cervical cancer (46, 47), so in this study we analyzed valproic acid effects on E-cadherin expression in HPV positive cell lines and HPV negative cell lines.

Our results showed that E-cadherin expression is increased in HPV positive cell lines (HeLa and TC1) and HPV negative cell lines (MKN45 and HCT116); this result is consistent with previous studies. The expression of E-cadherin is up-regulated by VPA in LNCaP, DU145, PC3, and luminescent PC3 prostate cancer cell lines and prostate cancer xenograft mouse models (48). The VPA effects on ovarian cancer using human ovarian cancer cell line SKOV3 and a human ovarian cancer model transplanted subcutaneously in nude mice showed increased expression of E-cadherin and reduced matrix metalloproteinase-9 and VEGF in vitro and in vivo (49). VPA and SAHA treatment, in combination with all-trans retinoic acid (ATRA), restore E-cadherin, TSGs RARb2, P53, and P21CIP1 expression in human cervical cancer cells (50). It has been also reported that S-valproate reduces transcriptional suppressor of E-cadherin proteins vimentin and ZEB1 and increases E-cadherin protein expression in non-small cell lung cancer (51). Based on previous studies, VPA treatment increases the expression of E-cadherin in RM1 and PC3 cell lines, and might be useful to inhibit E-cadherin-mediated migration in prostate cancer cells (52, 53).

The effects of VPA on cervical cancer cell lines have been also investigated before. VPA has shown a growth inhibitory effect on HeLa, SiHa, and CaSki cervical cancer cell lines (54, 55). VPA increases p53 transcription and protects it from degradation by E6 (54). Evaluating the effects of VPA on cervical cancer cell lines HeLa, SiHa, and CaSki and in vivo cancer models demonstrated increased p21 expression and histone H3 acetylation. Chronic treatment of VPA significantly decreased tumor growth and improved survival in tumor xenograft studies (56). Another study revealed that VPA treatment suppresses cell growth and induces cell cycle arrest in human cervical cancer HeLa cells, and also increases the tumor suppressor, Notch1 (57).

According to our findings, E-cadherin augmentation in HPV positive cell lines, HeLa and TC-1, is higher than HPV negative cell lines, MKN45 and HCT116. Previous studies have showed the effect of HPV E7 oncoprotein on E-cadherin expression, one study revealed that the expression of the HPV16 E7 in MDCK cells reduces the expression of E-cadherin (30), and suppression of HPV E7 using siRNA in HPV16 transformed human keratinocytes restores the E-cadherin expression in this cell (31). We studied the effects of VPA on HPV E7 expression in HeLa and TC1 cell lines; VPA significantly decreased HPV E7 mRNA level in both cell lines. This reduction of HPV E7 expression by VPA might lead to more augmentation of E-cadherin in HPV positive cell lines.

Conclusion
VPA increases E-cadherin expression in HPV positive cell lines and HPV negative cell lines; however, E-cadherin augmentation in HPV positive cell lines is higher than HPV negative cell lines. VPA decreases HPV E7 mRNA level in HeLa and TC-1 cell lines, which might lead to augmentation of E-cadherin in HPV positive cell lines. VPA showed anticancer properties and could potentially be a promising candidate for further cervical cancer treatment.

Acknowledgement
The authors thank the entire staff of Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. This Research was supported by Tehran University of Medical Sciences under research No. 93-03-27-25127.
References

1. Pisani P, Bray F, Parkin DM. Estimates of the worldwide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97:72-81.

2. Rossi A, Claire S, Balsamo M, Pierimarchi P, Santoro MG. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyper thermo chemotherapy efficacy in cervical cancer. Cancer Res 2006; 66:7678–7685.

3. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6:204.

4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-3450.

5. Boyer SN, Wazer DE, Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56:4620-4624.

6. Scheffner M, Werness BA, Hiubregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-1136.

7. Gonzalez Martin A. Molecular biology of cervical cancer: Clin Transl Oncol 2007; 9:347-354.

8. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8:1409-1420.

9. Wang GQ, Allis CD, Chi P. Chromatin remodeling and cancer: Part I: covalent histone modifications. Trends Mol Med 2007; 13:363-372.

10. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancers: causes and therapies. Nat Rev Cancer 2001; 1:194-202.

11. Bellarosa D, Bressan A, Bigioni M, Pariani M, Maggi CA, Binasci M. SAHA/ Vorinostat induces the expression of the CD13 receptor/ ligand system and enhances apoptosis mediated by soluble CD13 receptor in a human breast cancer cell line. Int J Oncol 2012; 41:1486-1494.

12. Feng L, Pan M, Sun J, Lu H, Shen Q, Zhang S, et al. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. J Mol Med 2013; 91:49-58.

13. Takai N, Narahara H. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 2007; 14:2548-2553.

14. Johanssens CU, Johanssens SI. Valproate: past, present, and future. CNS Drug Rev 2003; 9:199-216.

15. Cinatl JR, Cinatl J, Driever PH, Kothchetkov R, Pouckova P, Kornhuber B, et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997; 8:959-963.

16. Blaheta RA, Michaelis M, Driever PH, Cinatl JR. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005; 25:383-397.

17. Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002; 22:492-511.

18. Blaheta RA, Nau H, Michaelis M, Cinatl J Jr. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 2002; 9:1417-1433.

19. Beecken WD, Engl T, Ogbomo H, Relja B, Cinatl J, Berete-Hahn J, et al. Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells. Int Immunopharmacol 2005; 5:757-769.

20. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res 2008; 28:3815-3826.

21. Berx G, Staes K, van Hengel J, Molemans F, Bussemakers MJ, van Bokhoven E. Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 1995; 26:281-289.

22. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7:415-428.

23. Simeos-Correia J, Figueiredo J, Oliveira C, van Hengel J, Seruca R, van Roy F, et al. Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. Hum Mol Genet 2008; 17:3566-3576.

24. Oliveira C, Senj J, Kaurah P, Pinheiro H, Sanges R, Haergert A, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009; 18:1545-1555.

25. Pinheiro H, Bordeira-Carrico R, Seixas S, Carvalho J, Senj J, Oliveira P, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010; 19:943-952.

26. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68:3645-3654.

27. Karam R, Carvalho J, Bruno I, Grazziadio C, Senj J, Huntsman D, et al. The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. Oncogene 2008; 27:4255-4260.

28. Larue L, Bellacosa A. Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 39 kinase/akt pathways. Oncogene 2005; 24:7443-7454.

29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001; 25:402-408.

30. Martel C, Harper F, Cereghini S, Nae V, Mareel M, Cremsi M. Inactivation of retinoblastoma family proteins by SV40 T antigen results in creation of a hepatocyte growth factor/scatter factor autocrine loop associated with an epithelial-fibroblastoid conversion and invasiveness. Cell Growth Differ 1997; 8:165-178.

31. Caberg JH, Hubert PM, Begon DY, Herfs MF, Roncarati PJ, Boniver JJ, et al. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. Carcinogenesis 2008; 29:1441-1447.

32. Adhya D, Basu A. Epigenetic modulation of host: new insights into immune evasion by viruses. J Biosci 2010; 35:647-663.
33. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000;9:2395-2402.
34. Razin A. CpG methylation, chromatin structure and gene silencing—a three-way connection. EMBO J 1998; 17:4905-4908.
35. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000; 24:88-91.
36. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. Dnmt5a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001; 20:2536-2544.
37. Fuks F, Hurd PJ, Deplus R, Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 2003; 31:2305-2312.
38. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003; 278:4035-4040.
39. Burgers W, Fuks F, Kouzarides T. DNA methyltransferases get connected to chromatin. Trends Genet 2002; 18:275-277.
40. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-454.
41. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005; 6:622-634.
42. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 39 kinase/AKT pathways. Oncogene 2005; 24:7443-7454.
43. Hagemann T, Bozanovic T, Hooper S, Ljubic A, Slettenaar VI, Wilson JL, et al. Molecular profiling of cervical cancer progression. Br J Cancer 2007; 6:321-328.
44. Yuecheng Y, Hongmei L, Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 2006; 23:65-74.
45. Carico E, Atlante M, Bucci B, Nofroni I, Vecchione A. E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma. Gynecol Oncol 2001; 80:156-161.
46. D’Costa ZJ, Jolly C, Androphy EJ, Mercer A, Matthews CM, Hibma MH. Transcriptional repression of E-Cadherin by Human Papillomavirus Type 16 E6. PLoS One 2012; 7:e48954.
47. Laurson J, Khan S, Chung R, Cross K, Raj K. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 2010; 31:918-926.
48. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, et al. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006; 26:7561-7574.
49. Shan Z, Feng-Nian R, Jie G, Ting Z. Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. Asian Pac J Cancer Prev 2012; 13:3977-3982.
50. Feng D, Wu J, Tian Y, Zhou H, Zhou Y, Hu W, et al. Targeting of histone deacetylases to repress tumor suppressor genes and its therapeutic potential in a human cervical cancer xenograft model. PLoS One 2013; 19:8.
51. Moody TW, Switzer C, Santana-Flores W, Ridnour LA, Berna M, Thill M, et al. Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer 2010; 68:154-160.
52. Zhang L, Wang G, Wang L, Song C, Wang X, Kang J. Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression. Pharmazie 2011; 66:614-618.
53. Iacopino F, Urbano R, Graziani G, Muzi A, Navarra P, Sica G. Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. Int J Oncol 2008; 32:1293-1303.
54. de la Cruz-Hernández E, Pérez-Cárdenas E, Contreras-Paredes A, Cantú D, Mohar A, Lizano M, et al. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Viral J 2007; 4:18.
55. Chen J, Ghazawi FM, Balakar W, Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 2006; 4:5:71.
56. Sami S, Høtt N, Xu HM, Shen Z, Huang X. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 2008; 144:357-362.
57. Tsai C, Leslie JS, Franko-Tobin LG, Prasal MC, Yang T, Vienna Mackey L, et al. Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. Arch Gynecol Obstet 2013; 288:393-400.